[1] Gao A Q, Liu X, Lin W L, et al. Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity [J]. J Immunother Cancer, 2021, 9(3): e001536. [2] Martín-Villa J M, Vaquero-Yuste C, Molina-Alejandre M, et al. HLA-G: too much or too little? Role in cancer and autoimmune disease [J]. Front Immunol, 2022, 13: 796054. [3] Fan J, Li J Y, Han J B, et al. Expression of leukocyte immunoglobulin-like receptor subfamily B expression on immune cells in hepatocellular carcinoma [J]. Mol Immunol, 2021, 136: 82-97. [4] Luo Z W, Health S L, Li M, et al. Variation in blood microbial lipopolysaccharide (LPS) contributes to immune reconstitution in response to suppressive antiretroviral therapy in HIV [J]. EBioMedicine, 2022, 80: 104037. [5] Lin T Y, Lian Z J, Yao C X, et al. CdSe quantum dots labeled Staphylococcus aureus for research studies of THP-1 derived macrophage phagocytic behavior [J]. RSC Adv, 2019, 10: 260-270. [6] Shukla N, Sato-Kaneko F, Yao S Y, et al. A triple high throughput screening for extracellular vesicle inducing agents with immunostimulatory activity [J]. Front Pharmacol, 2022, 13: 869649. [7] Tang X R, Aljahdali B, Alasiri M, et al. A method for high transfection efficiency in THP-1 suspension cells without PMA treatment [J]. Anal Biochem, 2018, 544: 93-97. [8] 高舒玉, 邹淑梅, 柳德灵, 等. 维生素D受体特异性shRNA慢病毒载体及ASMCs稳转株的构建 [J]. 中国临床药理学杂志, 2020, 36(9): 1096-1099. [9] 闫海龙, 陈晓旭, 朱晋生, 等. 猪Utx慢病毒过表达/干扰载体的构建和病毒包装 [J]. 家畜生态学报, 2017, 38(8): 7-13. [10] Chen X, Gao A, Zhang F, et al. ILT4 inhibition prevents TAM-and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation [J]. Theranostics, 2021, 11(7):3392-3416. [11] Bashirova A A, Martin-Gayo E, Jones D C, et al. LILRB2 interaction with HLA class I correlates with control of HIV-1 infection [J]. PLoS Genet, 2014, 10(3): e1004196. [12] ClinicalTrials.gov. Phase 1/2 first-in-human (FIH) study of leukocyte immunoglobulin-like receptor B2 (LILRB2) inhibitor monoclonal antibody (mAb) JTX-8064, as monotherapy and in combination with a programmed cell death receptor-1 (PD-1) inhibitor, in adult subjects with advanced refractory solid tumor malignancies [DB/OL]. (2021-01-13) [2021-03-01]. https://www.clinicaltrials.gov/ct2/show/NCT04669899?cond=LILRB2&draw=2&rank=1. [13] Immue-Onc. Immune-Onc therapeutics announces first patient dosed in phase I trial evaluating IO-202, a first-in-class antibody for the treatment of acute myeloid leukemia [EB/OL]. (2020-09-16) [2021-03-01]. https://www.immune-onc.com/pr-posts/immune-onc-therapeutics-announces-first-patient-dosed-in-phase-i-trial-evaluating-io-202-a-first-in-class-antibody-for-the-treatment-of-acute-myeloid-leukemia. |